# A Phase IIb Study to Evaluate a Long-Acting Intramuscular Regimen for Maintenance of Virologic Suppression (Following Induction With an Oral Regimen of GSK1265744 and Abacavir/Lamivudine) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected, Antiretroviral Therapy-Naive Adult Subjects

> **NCT02120352** · PHASE2 · COMPLETED · sponsor: **ViiV Healthcare** · enrollment: 309 (actual)

## Conditions studied

- Infection, Human Immunodeficiency Virus
- HIV Infections

## Interventions

- **DRUG:** CAB Oral Tablets
- **DRUG:** CAB LA
- **DRUG:** ABC/3TC Oral tablets
- **DRUG:** RPV Oral Tablets
- **OTHER:** HAART
- **DRUG:** RPV

## Key facts

- **NCT ID:** NCT02120352
- **Lead sponsor:** ViiV Healthcare
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-04-28
- **Primary completion:** 2015-08-13
- **Final completion:** 2023-04-20
- **Target enrollment:** 309 (ACTUAL)
- **Last updated:** 2024-06-12

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02120352

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02120352, "A Phase IIb Study to Evaluate a Long-Acting Intramuscular Regimen for Maintenance of Virologic Suppression (Following Induction With an Oral Regimen of GSK1265744 and Abacavir/Lamivudine) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected, Antiretroviral Therapy-Naive Adult Subjects". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02120352. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*